Otonomy Inc (OTIC) Scheduled to Post Quarterly Earnings on Wednesday
Otonomy Inc (NASDAQ:OTIC) will announce its earnings results after the market closes on Wednesday, November 1st. Analysts expect the company to announce earnings of ($0.84) per share for the quarter.
Otonomy (NASDAQ:OTIC) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.80) by $0.03. Otonomy had a negative net margin of 7,123.01% and a negative return on equity of 58.32%. The company had revenue of $0.33 million for the quarter, compared to analyst estimates of $0.43 million. During the same quarter last year, the firm earned ($0.98) EPS. The firm’s quarterly revenue was up 312.5% compared to the same quarter last year. On average, analysts expect Otonomy to post $-3.07 EPS for the current fiscal year and $-2.31 EPS for the next fiscal year.
Otonomy Inc (NASDAQ OTIC) opened at 3.35 on Wednesday. The company’s market cap is $101.52 million. Otonomy Inc has a 12-month low of $3.15 and a 12-month high of $21.15. The company’s 50 day moving average is $3.41 and its 200 day moving average is $12.51.
Several equities research analysts recently weighed in on OTIC shares. BidaskClub cut shares of Otonomy from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. Piper Jaffray Companies cut shares of Otonomy from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $32.00 to $8.00 in a research report on Wednesday, August 30th. J P Morgan Chase & Co upgraded shares of Otonomy from a “neutral” rating to an “overweight” rating and set a $28.00 price target on the stock in a research report on Tuesday, August 15th. Cowen and Company restated an “outperform” rating and issued a $9.00 price target (down previously from $55.00) on shares of Otonomy in a research report on Thursday, August 31st. Finally, SunTrust Banks, Inc. restated a “buy” rating and issued a $15.00 price target (down previously from $45.00) on shares of Otonomy in a research report on Thursday, August 31st. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $10.00.
Otonomy Company Profile
Otonomy, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company’s product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase.
Receive News & Ratings for Otonomy Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy Inc and related companies with MarketBeat.com's FREE daily email newsletter.